Merck Toekomstige groei

Future criteriumcontroles 2/6

Merck zal naar verwachting groeien in winst en omzet met respectievelijk 8.3% en 3.1% per jaar. De winst per aandeel zal naar verwachting groeien met 8.9% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 38% zijn.

Belangrijke informatie

8.3%

Groei van de winst

8.91%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	11.3%
Inkomstengroei	3.1%
Toekomstig rendement op eigen vermogen	37.95%
Dekking van analisten	Good
Laatst bijgewerkt	13 Feb 2026

Recente toekomstige groei-updates

Merck & Co., Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Nov 02

Recent updates

The Oncology Anchor: Why Merck’s 46% Discount Defies the Keytruda Cliff

Jan 30Merck’s 2026 narrative is a high-stakes drama centered on Keytruda , the world’s top-selling cancer drug. For years, the market has treated Merck like a "one-trick pony" due to the looming 2028 "patent cliff," where Keytruda will lose its legal protection and face generic competition.

Merck (NYSE:MRK) Is Increasing Its Dividend To $0.85

Dec 02

Merck & Co., Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Nov 02

Shareholders Can Be Confident That Merck's (NYSE:MRK) Earnings Are High Quality

Aug 12

Winst- en omzetgroeiprognoses

NYSE:MRK - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2028	74,764	23,634	24,530	N/A	16
12/31/2027	70,445	21,504	23,675	N/A	20
12/31/2026	66,708	10,423	14,744	N/A	20
12/31/2025	65,011	18,254	N/A	N/A	N/A
9/30/2025	64,235	19,034	13,049	17,065	N/A
6/30/2025	63,616	16,406	14,722	18,534	N/A
3/31/2025	63,922	17,434	17,039	20,878	N/A
12/31/2024	64,168	17,117	18,096	21,468	N/A
9/30/2024	63,174	12,148	14,840	18,264	N/A
6/30/2024	62,480	13,736	13,147	16,690	N/A
3/31/2024	61,403	2,306	11,040	14,757	N/A
12/31/2023	60,115	365	9,143	13,006	N/A
9/30/2023	59,315	4,608	13,167	17,190	N/A
6/30/2023	58,311	3,111	10,828	15,075	N/A
3/31/2023	57,869	13,030	11,262	15,673	N/A
12/31/2022	59,283	14,519	14,707	19,095	N/A
9/30/2022	58,974	15,322	15,249	19,696	N/A
6/30/2022	57,169	16,641	14,398	18,891	N/A
3/31/2022	53,978	13,910	12,870	17,220	N/A
12/31/2021	48,704	12,345	9,661	14,109	N/A
9/30/2021	46,131	5,908	8,401	13,072	N/A
6/30/2021	43,906	3,665	6,953	11,897	N/A
3/31/2021	41,857	4,793	6,659	11,184	N/A
12/31/2020	41,518	4,519	5,812	10,241	N/A
9/30/2020	42,438	9,492	6,906	11,041	N/A
6/30/2020	43,906	9,070	7,996	11,645	N/A
3/31/2020	46,312	9,399	8,947	12,811	N/A
12/31/2019	39,121	5,690	10,071	13,440	N/A
9/30/2019	45,970	9,314	N/A	12,238	N/A
6/30/2019	44,367	9,362	N/A	10,805	N/A
3/31/2019	43,073	8,399	N/A	11,103	N/A
12/31/2018	42,294	6,220	N/A	10,922	N/A
9/30/2018	41,729	3,347	N/A	11,349	N/A
6/30/2018	41,259	1,341	N/A	7,385	N/A
3/31/2018	40,725	1,579	N/A	7,320	N/A
12/31/2017	40,122	2,394	N/A	6,451	N/A
9/30/2017	39,804	2,845	N/A	6,064	N/A
6/30/2017	40,016	5,086	N/A	10,206	N/A
3/31/2017	39,929	4,346	N/A	8,489	N/A
12/31/2016	39,807	3,920	N/A	10,376	N/A
9/30/2016	39,907	5,492	N/A	10,990	N/A
6/30/2016	39,444	5,133	N/A	11,330	N/A
3/31/2016	39,385	4,614	N/A	12,427	N/A
12/31/2015	39,498	4,442	N/A	12,538	N/A
9/30/2015	39,765	10,781	N/A	7,128	N/A
6/30/2015	40,249	9,850	N/A	8,165	N/A
3/31/2015	41,398	11,168	N/A	7,783	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei MRK ( 8.3% per jaar) ligt boven de spaarquote ( 3.4% ).

Winst versus markt: De winst van MRK ( 8.3% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 15.6% per jaar).

Hoge groeiwinsten: De winst van MRK zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van MRK ( 3.1% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 10.3% per jaar).

Hoge groei-inkomsten: De omzet van MRK ( 3.1% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen MRK zal naar verwachting over 3 jaar hoog zijn ( 38 %)

Ontdek groeibedrijven

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/02/18 10:47
Aandelenkoers aan het einde van de dag	2026/02/18 00:00
Inkomsten	2025/12/31
Jaarlijkse inkomsten	2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details over het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina; we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

"}]}

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Merck & Co., Inc. wordt gevolgd door 47 analisten. 20 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
David Toung	Argus Research Company
Charles Butler	Barclays
Luisa Hector	Berenberg

Merck Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Merck & Co., Inc. Provides Earnings Guidance for the Full Year 2026

Merck & Co., Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Merck & Co., Inc. Updates Earnings Guidance for the Year 2025

Merck & Co., Inc. Updates Sales Guidance for the Year 2025

Recent updates

Merck announces Health Canada Approves KEYTRUDA SC™, a Subcutaneous Formulation of Pembrolizumab Across Multiple Cancer Indications

Merck Advances Treatment of Bladder and Kidney Cancers with New Data At 2026 ASCO GU Cancers Symposium

Merck Announces the U.S. Food and Drug Administration Approves KEYTRUDA (Pembrolizumab and Berahyaluronidase Alfa-Pmph) and KEYTRUDA QLEX

Executive VP & General Counsel notifies of intention to sell stock

Chairman recently sold US$5.6m worth of stock

Merck Announces Health Canada Approval of ENFLONSIA for the Prevention of RSV in Newborns and Infants

Chairman notifies of intention to sell stock

Full year 2025 earnings: EPS misses analyst expectations

Merck & Co., Inc. Provides Earnings Guidance for the Full Year 2026

Third quarter dividend of US$0.85 announced

The Oncology Anchor: Why Merck’s 46% Discount Defies the Keytruda Cliff

Merck Declares Dividend on Common Stock for the Second-Quarter of 2026, Payable on April 7, 2026

MSD Reportedly Ends Takeover Talks with Revolution Medicines

Merck Reportedly in Talks to Buy Revolution in Up to $32 Billion Deal

Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib in Combination with KEYTRUDA QLEX (Pembrolizumab and Berahyaluronidase Alfa-Pmph) in Certain Patients with Advanced NSCLC

Merck Reaches Agreement with U.S. Government to Expand Access to Medicines and Lower Costs for Americans

Merck Announces KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery

Merck Receives Positive EU Chmp Opinion for Expanded Use of Winrevair™? (Sotatercept) in Adults with Pulmonary Arterial Hypertension (Pah, Who* Group 1 Pulmonary Hypertension)

Upcoming dividend of US$0.85 per share

Merck (NYSE:MRK) Is Increasing Its Dividend To $0.85

Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025

FDA Approves Merck and KEYTRUDA (Pembrolizumab) and KEYTRUDA QLEX (Pembrolizumab and Berahyaluronidase Alfa-Pmph

Third quarter dividend increased to US$0.85

Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravir (Dor/Isl) in Treatment-1 Infection

Merck Declares Dividend for the First Quarter of 2026, Payable on January 8, 2026

Merck Reportedly Close on A Deal to Buy Cidara

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly ReducedDL-C in Adults with Heterozygous Familial Hypercholesterolemia in Phase 3 CORALreef HeFH Trial

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly ReducedDL-C in Phase 3 CORALreef Lipids Trial

Merck & Co., Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Merck & Co., Inc. Updates Earnings Guidance for the Year 2025

European Commission Approves KEYTRUDA® (Pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)

Merck Announces Positive Topline Results from the Phase 3 LITESPARK-022 Trial in Patients with Clear Cell Renal Cell Carcinoma

Merck & Co., Inc. Receives FDA Approval For Updated Indication Of WINREVAIR In Adults With PAH

Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio At AHA Scientific Sessions 2025

Merck & Co., Inc. Announces the Presentation of Findings from Systematic Review of Studies on the Ep Epiiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CapvaXIVE

Merck & Co., Inc. Announces New Long-Term Data Highlighting the Sustained Survival Benefits of Keytruda® (Pembrolizumab), Merck’s anti-PD-1 Therapy, in Treating Non-Small Cell Lung Cancer (NSCLC )

Daiichi Sankyo and Merck Demonstrate Clinically Meaningful Response Rates for Raludotatug Deruxtecan in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Merck and Eisai Announces Long-Term Follow-Up Data Continued to Show Durable Benefit of KEYTRUDA®? (Pembrolizumab) Plus LENVIMA®? (lenvatinib)

Merck & Co., Inc. Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients with Platinum-Resistant Recurrent Ovarian Cancer

Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravir/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infection

Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Early Stages of Disease At ESMO 2025

Merck Expands Tulisokibart Clinical Development Program with Initiation of Phase 2B Trials in Three Additional Immune-Mediated Inflammatory Diseases

Investor sentiment improves as stock rises 15%

Merck Announces Positive Results from the Phase 3 HYPERION Trial Evaluating Winrevair

FDA Approves Merck’s KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA (pembrolizumab)

Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer

Daiichi Sankyo and Merck Announce Raludotatug Deruxtecan Receives Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab

Merck & Co., Inc. Announces Positive Results from the Phase 3 STRIDE-13 Trial Evaluating CapvaXIVE

Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in Ideate-Lung01 Phase 2 Trial

Upcoming dividend of US$0.81 per share

Merck & Co., Inc. Announces Positive Topline Results from the Phase 3 CORALreef Lipids Trial Evaluating the Safety and Efficacy of Enlicitide Decanoate

Merck's First Patient Dosed in the HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor

Merck Demonstrates Ongoing Commitment to Advancing Cardiovascular Disease Management and Patient Care with New Data at the European Society of Cardiology Congress 2025

Daiichi Sankyo and Merck Announce U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer

Health Canada Approves KEYTRUDA for Patients with Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma Tumours That Are PD-L1 (CPS) Positive as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined with Radiotherapy with or Without Cisplatin Then as Monotherapy

Shareholders Can Be Confident That Merck's (NYSE:MRK) Earnings Are High Quality

Merck Announces Positive Topline Results from the Phase 3 KEYTRUDA Trial in Patients with Muscle-Invasive Bladder Cancer

Second quarter 2025 earnings: EPS misses analyst expectations

Merck & Co., Inc. Updates Sales Guidance for the Year 2025

First quarter dividend of US$0.81 announced

Merck Declares Fourth-Quarter 2025 Dividend, Payable on October 7, 2025

Merck & Co., Inc. to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill

U.S. FDA Accepts New Drug Application for Merck's Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection

Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025

FDA Grants Priority Review for WinrevaIR (sotatercept-csrk) to Update Label Based on Results from Zenith Trial of Merck & Co., Inc

Merck & Co., Inc.(NYSE:MRK) dropped from Russell 1000 Dynamic Index

Acip Recommends Use of Merck's Enflonsia for Prevention of Respiratory Syncytial Virus

Merck Announces Phase 3 HYPERION Study of Winrevair Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH)

Merck Manuals Launches AI-Powered Search Tool, Providing Enhanced Access to Trusted Medical Information and Resources

IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer